Physician profile
Albert O Edwards
NPI 1215930763
$9,224.04
in general payments reported to CMS, 2019-2025
28 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 75% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2021: $142 · 2022: $1,048 · 2023: $1,149 · 2024: $5,576 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,503 · Food and Beverage: $1,328 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,502.90 |
| Food and Beverage | $1,328.45 |
| Travel and Lodging | $969.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | $5,502.90 | 2024 | Veracity Surgical |
| Carl Zeiss Meditec USA, INC. | $1,053.68 | 2023 | Veracity Surgical, Iolmaster 700, Cirrus Hd-Oct |
| Boehringer Ingelheim International Gmbh | $934.00 | 2022 | |
| Bausch & Lomb Americas INC. | $218.39 | 2025 | Stellaris |
| Apellis Pharmaceuticals, INC. | $208.97 | 2022-2023 | |
| Alcon Research LLC | $181.74 | 2025 | |
| Rxsight INC | $159.28 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Alcon Vision LLC | $147.00 | 2025 | Clareon Panoptix Pro |
| Genentech, INC. | $142.67 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $129.93 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $115.25 | 2019 | |
| Sun Pharmaceutical Industries INC. | $107.49 | 2025 | |
| Heidelberg Engineering, INC. | $93.70 | 2025 | Spectralis |
| Regeneron Pharmaceuticals, INC. | $84.60 | 2025 | Eylea Hd |
| Novo Nordisk INC | $54.32 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.68 | 2025 | |
| Biotissue Holdings INC. | $20.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.54 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.